Sino Biopharmaceutical (HKG:1177) presented preliminary data from its first-in-human Phase I clinical study of cancer drug TQB2102 at the 2025 ASCO Annual Meeting, according to a Tuesday filing with the Hong Kong Exchange.
The company reported encouraging results, with response rates of up to 70% in certain HER2-positive cancers, including breast and gastric cancers -- even among patients who had not responded to prior treatments.
Side effects were described as manageable, with only a few cases of serious lung-related adverse events.
TQB2102 is currently in Phase 3 trials and, if successful, could become the world's first approved bispecific HER2 antibody-drug conjugate (ADC), the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。